Recent interviews and updates from medical experts shed light on the evolving landscape of Alzheimer’s disease diagnostics and therapies. Dr. Phillip Kuo discussed the newly updated appropriate use criteria (AUC) for amyloid PET imaging, reflecting the impact of recent FDA-approved anti-amyloid therapies, including lecanemab and donanemab. The new guidelines also incorporate tau PET imaging for patients with mild cognitive impairment, addressing the limitations of amyloid PET in correlating with clinical symptoms. In additional research, a study involving over 2,200 women highlighted that those with high scores on the COronary Risk Score in Women (CORSWO) model had over a fourfold increased risk of major adverse coronary events. Furthermore, new guidelines were published regarding the use of imaging techniques like CT, MRI, and PET/CT in managing ovarian and colorectal cancer peritoneal metastases. The European Association of Nuclear Medicine (EANM) meeting introduced the AnyScan Trio SPECT/CT TheraMax scanner, designed for theranostic imaging, and the FDA has cleared new Centiloid scoring and tau PET quantification tools to better diagnose Alzheimer’s disease.
Tue, 14 Jan 2025 01:04:38 GMT | Diagnostic Imaging